aid: discgenics
name: DiscGenics
description: 'DiscGenics is a privately held, late-stage clinical biopharmaceutical
  company headquartered in Salt Lake City, Utah, developing allogeneic, cell-based
  regenerative biologic therapies for degenerative diseases of the spine. Its lead
  candidate, IDCT (rebonuputemcel), is a single-injection allogeneic discogenic progenitor
  cell therapy for symptomatic mild-to-moderate lumbar degenerative disc disease, manufactured
  under cGMP from donated adult human intervertebral disc tissue and granted FDA Regenerative
  Medicine Advanced Therapy (RMAT) and Fast Track designations. The company is running
  a US Phase III program (the PIVOT and CONFIRM studies) alongside a clinical study
  in Japan. DiscGenics is a therapeutics developer, not a software vendor: it publishes
  no developer portal, API, SDK or machine-readable specification of any kind.'
image: http://static1.squarespace.com/static/59d2b1d812abd948b8707a48/t/59e93fb88a02c760fefcc86b/1774284572317/Discgenics-Logo-White.png?format=1500w
url: https://raw.githubusercontent.com/api-evangelist/discgenics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-12'
modified: '2026-08-12'
tags:
- Company
- Biotechnology
- Biopharmaceutical
- Regenerative Medicine
- Cell Therapy
- Healthcare
- Life Sciences
- Clinical Trials
- Spine
- Utah
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/discgenics-domain-security.yml
- type: LLMsTxt
  url: llms/discgenics-llms.txt
- type: Website
  url: https://www.discgenics.com/
- type: About
  url: https://www.discgenics.com/about-us
- type: Blog
  url: https://www.discgenics.com/ceos-blog
- type: News
  url: https://www.discgenics.com/news
- type: Contact
  url: https://www.discgenics.com/contact
- type: TermsOfService
  url: https://www.discgenics.com/terms-of-use
- type: PrivacyPolicy
  url: https://www.discgenics.com/privacy-policy
- type: Investors
  url: https://www.discgenics.com/investors-and-media
- type: Careers
  url: https://www.discgenics.com/about-us#careers
- type: LinkedIn
  url: https://www.linkedin.com/company/discgenics/
- type: Facebook
  url: https://www.facebook.com/DiscGenics
- type: ClinicalTrials
  url: https://clinicaltrials.gov/search?spons=DiscGenics
- type: PatientTrialSite
  url: https://www.dddtrial.com/
x-enrichment:
  date: '2026-08-12'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    DiscGenics is a late-stage clinical biopharmaceutical company whose product is an
    injectable allogeneic cell therapy (IDCT/rebonuputemcel), not software — its entire
    web presence is a bilingual Squarespace marketing site whose 139-URL sitemap contains
    only company, science, pipeline, patient and news pages, with no developer, API or
    documentation section, and no public GitHub organization.
  evidence:
  - url: https://www.discgenics.com/openapi.json
    status: 404
  - url: https://www.discgenics.com/docs
    status: 404
  - url: https://www.discgenics.com/.well-known/agent-card.json
    status: 404
  - url: https://www.dddtrial.com/.well-known/agent-card.json
    status: 404
  - url: https://www.discgenics.com/sitemap.xml
    status: 200
  - url: https://api.github.com/search/users?q=discgenics
    status: 200
  checked: '2026-08-12'